latest breakthroughs in non-invasive glucose monitoring. Keep users updated on trials, prototype unveilings, and regulatory milestones in optical glucose sensors. Perfect for a news aggregator feed.
Latest breakthroughs in non-invasive optical glucose monitoring
Curated reading list of 9 sources covering registered human studies, physiological datasets, optical prototypes, theoretical sensor designs, and regulatory context through 15 August 2026. The reviewed evidence does not verify a post-2025 FDA clearance for a truly non-invasive optical glucose sensor; conventional minimally invasive CGM milestones are not classified here as optical or non-invasive.[1][2]
Human studies, trials, and datasets
Sources most relevant to human evaluation or data resources for non-invasive optical glucose estimation. The search found limited directly matching peer-reviewed clinical evidence, and the Raman registry entry should be checked for current recruitment and study details.
clinicaltrials.gov
nih.gov
nih.govOptical prototypes and device unveilings
Recent news and technical coverage of Raman, near-infrared, and other optical prototype announcements. Some reports lack publication dates, sample sizes, detailed clinical methods, or independently verifiable validation data.
news-medical.net7 Dec 2025
medicaldesignandoutsourcing.com
pharmacytimes.com22 Apr 2024Emerging optical sensor designs
Research on next-generation optical architectures, including a 2026 surface-plasmon-resonance design. The SPR paper is a numerical and theoretical study, not a human trial or clinical validation dataset.[[cite:10]]
doi.org11 Aug 2026Regulatory context and milestone tracking
Official FDA pages useful for monitoring glucose-device clearances and regulatory developments. The listed OTC and CGM documents concern CGM regulatory activity, not verified clearance of a truly non-invasive optical glucose sensor.[[cite:12]][[cite:13]]
Scoped-search caveat: searches of ClinicalTrials.gov and selected academic indexes did not establish a robust post-2025 human-trial record specifically for optical, non-invasive glucose sensors. Prototype coverage is therefore stronger than confirmed clinical or regulatory evidence, and undated reports should be treated as preliminary.[16][17][18]
Create your account to keep this answer and continue from it later.
Let's look at alternatives:
- Modify the query.
- Start a new thread.
- Remove sources (if manually added).
